World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
44885
World Ranking
17790
National Ranking
8876

Overview

D. Craig Allred is affiliated with The University of Texas Health Science Center at San Antonio in the United States. Their research spans multiple fields, including biochemistry, genetics and molecular biology, computer science, and medicine. The subfields of study associated with their work include genetics, computational theory and mathematics, and oncology.

They have contributed to research in several scientific topics, notably:

  • Estrogen and related hormone effects
  • Computational drug discovery methods
  • HER2/EGFR in cancer research

A significant recent publication authored by D. Craig Allred is titled "Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031" published in 2020 through UNC Libraries.

Their collaborative network includes frequent coauthors such as Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Li Lin, and Jacqueline Snider. These collaborations reflect an interdisciplinary approach combining clinical and computational research methods.

D. Craig Allred's publications have appeared in venues such as UNC Libraries, and their work contributes to a broad understanding of cancer biology and treatment, particularly in regards to hormone-related breast cancer and computational methods for drug discovery.

Best Publications

  • American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

    M. Elizabeth H. Hammond;Daniel F Hayes;Mitch Dowsett;D Craig Allred

  • American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

    Antonio C. Wolff;M. Elizabeth H. Hammond;Jared N. Schwartz;Karen L. Hagerty

  • Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer

    Jennet M. Harvey;Gary M. Clark;C. Kent Osborne;D. Craig Allred

  • Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi

  • Prognostic Factors in Breast Cancer

    Patrick L. Fitzgibbons;Patrick L. Fitzgibbons;David L. Page;Donald Weaver;Ann D. Thor

  • Whole-genome analysis informs breast cancer response to aromatase inhibition

    Matthew J. Ellis;Li Ding;Dong Shen;Jingqin Luo

  • Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

    Jenny C. Chang;Eric C. Wooten;Anna Tsimelzon;Susan G. Hilsenbeck

  • Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer

    C. Kent Osborne;Valerie Bardou;Torsten A. Hopp;Gary C. Chamness

  • Association of p53 Protein Expression With Tumor Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast Cancer

    D. C. Allred;G. M. Clark;R. Elledge;S. A. W. Fuqua

  • Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement

    Richard J. Santen;D. Craig Allred;Stacy P. Ardoin;David F. Archer

  • American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

    M. Elizabeth H. Hammond;Daniel F. Hayes;Antonio C. Wolff;Pamela B. Mangu

  • Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

    Matthew J. Ellis;Vera J. Suman;Jeremy Hoog;Li Lin

  • HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

    D C Allred;G M Clark;A K Tandon;R Molina

  • Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase

    M. Carolina Gutierrez;Simone Detre;Stephen Johnston;Syed K. Mohsin

  • Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.

    D.Craig Allred;Gary M. Clark;Rafael Molina;Atul K. Tandon

  • Histological and biological evolution of human premalignant breast disease.

    D C Allred;S K Mohsin;S A Fuqua

  • Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice.

    C L Arteaga;L J Kitten;E B Coronado;S Jacobs

  • Aberrant subcellular localization of BRCA1 in breast cancer.

    Yumay Chen;Chi Fen Chen;Daniel J. Riley;D. Craig Allred

  • How to use prognostic factors in axillary node-negative breast cancer patients.

    McGuire Wl;Tandon Ak;Allred Dc;Chamness Gc

  • Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor-Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24

    D. Craig Allred;Stewart J. Anderson;Soonmyung Paik;D. Lawrence Wickerham

Frequent Co-Authors

C. Kent Osborne
C. Kent Osborne Baylor College of Medicine
Gary M. Clark
Gary M. Clark The University of Texas Health Science Center at San Antonio
Suzanne A. W. Fuqua
Suzanne A. W. Fuqua Baylor College of Medicine
Susan G. Hilsenbeck
Susan G. Hilsenbeck Baylor College of Medicine
Daniel Medina
Daniel Medina Baylor College of Medicine
Peter O'Connell
Peter O'Connell Virginia Commonwealth University
Antonio C. Wolff
Antonio C. Wolff Johns Hopkins University
Daniel F. Hayes
Daniel F. Hayes University of Michigan–Ann Arbor
William L. McGuire
William L. McGuire The University of Texas Health Science Center at San Antonio
Kornelia Polyak
Kornelia Polyak Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Advancing your career in medicine isn’t limited to the traditional MD path. There are several flexible online degree options that can open doors to specialized healthcare roles with strong job prospects, while also considering your schedule and budget.

For those interested in leadership and administration, pursuing an mha degree cost is a key factor when choosing a program. Online MHA degrees often offer the balance of affordability and quality education. If you’re already a nurse looking to reach the top of clinical practice, an accelerated 1 year dnp program online can fast-track your journey to advanced practice and leadership.

Pharmacy professionals might consider an online pharmd to transition into clinical or research roles. Those interested in the intersection of healthcare and technology may find value in online rhit degree programs, preparing you for positions managing patient data and health information systems.

No matter your background, exploring these online pathways can help you enhance your qualifications and expand your impact within the healthcare sector.

Best Scientists Citing D. Craig Allred

Trending Scientists

Recently Published Articles